Pentadecanoic Acid (C15:0)New
Pentadecanoic acid (C15:0) is an odd-chain saturated fatty acid found in small amounts in whole dairy fat and some fish, and the active ingredient in fatty15. It has been proposed as a newly essential fatty acid that stabilizes cell membranes, supports mitochondrial function, and protects against ferroptosis — an iron-driven, lipid-peroxidation form of cell death. The first human supplementation trial — a 2024 double-blind, randomized, placebo-controlled study in 30 young adults with overweight or obesity (The Journal of Nutrition) — gave 200 mg/day for 12 weeks and confirmed it was safe and well tolerated with no significant adverse events, raising circulating C15:0 by 1.88 ug/mL versus placebo. In the half of supplemented participants who reached a blood level above 5 ug/mL, there were significantly greater improvements in liver enzymes (ALT fell 29 U/L; AST fell 6 U/L) and hemoglobin (up 0.60 g/dL) than in participants who did not reach that level (shown in the chart below). These are promising but preliminary findings from a small post-hoc subgroup and need confirmation in larger, longer trials. Mechanistic and review work (Venn-Watson, Metabolites 2024; Scientific Reports 2020) frames low dietary C15:0 as a possible "Cellular Fragility" deficiency state linked to accelerated-aging conditions, and a 2025 preclinical rat study reported reduced liver fibrosis and ferroptosis markers. Because the free-fatty-acid form is the studied form, quality products use pure, third-party-tested C15:0. Individual results vary; this is educational information, not medical advice or a claim to diagnose, treat, cure or prevent any disease — discuss supplementation with your physician.
Mechanism of Action
C15:0 integrates into cell membranes, increasing their stability and resistance to lipid peroxidation and iron-driven cell death (ferroptosis). In cell-based and animal studies it has been reported to support mitochondrial function, activate AMPK, modulate mTOR signalling, and dampen inflammatory signalling — an activity profile that overlaps with several established metabolic and longevity compounds. Under the proposed "Cellular Stability Hypothesis" (Venn-Watson, Metabolites 2024), membranes may optimally need roughly 0.4-0.64% C15:0, and deficiency (at or below ~0.2% of circulating fatty acids) is hypothesized to raise susceptibility to ferroptosis-linked conditions such as type 2 diabetes, cardiovascular disease and fatty liver disease. Much of this mechanistic evidence remains preclinical; the first human supplementation RCT (2024) was small and showed benefits mainly in participants who reached higher circulating C15:0 levels.
Latest Research
Reviewed Aug 13, 2026
C15:0 (pentadecanoic acid) is an odd-chain saturated fatty acid that researchers have proposed as a newly essential nutrient. A 2024 review (Metabolites) advanced a 'Cellular Stability Hypothesis': by embedding in cell membranes, C15:0 may protect against lipid peroxidation and iron-driven cell death (ferroptosis), with circulating levels around 0.2% of total fatty acids marking deficiency and roughly 0.4% or higher associated with better long-term health. In cell-based work (Nutrients, 2023), C15:0 supported mitochondrial function and reduced inflammatory signalling across many human cell systems, with an activity profile that overlapped several established metabolic and longevity compounds. A 2024 randomized, placebo-controlled trial (The Journal of Nutrition) examined C15:0 supplementation in young adults with overweight or obesity. These findings are early and much of the mechanistic data is preclinical; C15:0 is a nutrient, not a treatment for any disease. Discuss supplementation with your physician.
Available at Peak Human Shop
Shop fatty15 — pure C15:0 (pentadecanoic acid)Latest Evidence · Population Data
Circulating C15:0 by Longevity Zone & Age
Circulating C15:0 as % of total fatty acids. Deficiency risk at ≤0.2%; roughly 0.4%+ associated with long-term health. Venn-Watson, Metabolites, 2024.
Latest research
- Venn-Watson S, et al. Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans. Scientific Reports, 2020.
- Venn-Watson S, Schork NJ. Pentadecanoic Acid (C15:0) shares clinically relevant cell-based activities with leading longevity-enhancing compounds. Nutrients, 2023.
- Venn-Watson S. The Cellular Stability Hypothesis: pentadecanoic acid (C15:0) deficiency and accelerated aging. Metabolites, 2024.
- Pentadecanoic Acid Supplementation in Young Adults with Overweight and Obesity: A Randomized Controlled Trial. The Journal of Nutrition, 2024.
Latest Research
Reviewed Oct 23, 2026
Pentadecanoic acid (C15:0) is an odd-chain saturated fat from whole dairy and some fish, and the active ingredient in fatty15. It has been proposed as a newly essential fatty acid that stabilizes cell membranes and guards against ferroptosis (iron-driven, lipid-peroxidation cell death). The first human supplementation trial — a 2024 double-blind, randomized, placebo-controlled study in 30 young adults with overweight or obesity (The Journal of Nutrition) — gave 200 mg/day for 12 weeks and was safe and well tolerated with no significant adverse events, raising circulating C15:0 by 1.88 µg/mL vs placebo (P = 0.003). In the half of supplemented participants who reached a blood level above 5 µg/mL, liver enzymes and hemoglobin improved significantly more than in those who did not — ALT fell 29 U/L more (P = 0.001), AST 6 U/L more (P = 0.014) and hemoglobin rose 0.60 g/dL more (P = 0.010), shown below. These are preliminary, small, post-hoc subgroup findings that need confirmation in larger trials. Mechanistically, Venn-Watson’s ‘Cellular Stability Hypothesis’ (Metabolites, 2024) frames low dietary C15:0 as a possible ‘Cellular Fragility’ deficiency state tied to accelerated-aging conditions, and a 2025 preclinical rat study reported reduced liver fibrosis and ferroptosis markers. This is educational information, not medical advice or a claim to diagnose, treat, cure or prevent any disease — discuss supplementation with your physician, especially if you have a medical condition or take prescription medications.
Randomized Trial · Overweight / Obese Young Adults · 200 mg/day · 12 weeks (n=30)
Liver Enzymes Fell Further in C15:0 Responders
Extra reduction in liver enzymes among supplemented participants who reached blood C15:0 >5 µg/mL, vs those who did not (taller = greater reduction)
In the first human trial of C15:0 (200 mg/day for 12 weeks in 30 young adults with overweight or obesity), supplementation raised circulating C15:0 by 1.88 µg/mL vs placebo (P = 0.003) and caused no significant adverse events. Half of the supplemented group reached a blood level above 5 µg/mL; in that subgroup, ALT fell 29 U/L more (P = 0.001) and AST 6 U/L more (P = 0.014) than in those who did not, alongside a 0.60 g/dL greater rise in hemoglobin (P = 0.010). These are small, post-hoc subgroup results from a single trial and may not generalize. Source: Robinson et al., The Journal of Nutrition, 2024 (doi:10.1016/j.tjnut.2024.07.030).
Latest research
- Robinson MK, et al. Pentadecanoic Acid Supplementation in Young Adults with Overweight and Obesity: A Randomized Controlled Trial. The Journal of Nutrition, 2024;154(9):2763–2771.
- Venn-Watson S. The Cellular Stability Hypothesis: Evidence of Ferroptosis and Accelerated Aging-Associated Diseases as a Newly Identified Nutritional Pentadecanoic Acid (C15:0) Deficiency Syndrome. Metabolites, 2024;14(7):355.
- Venn-Watson S, Lumpkin R, Dennis EA. Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans: could it be essential? Scientific Reports, 2020;10:8161.
- Pentadecanoic acid attenuates thioacetamide-induced liver fibrosis by modulating oxidative stress, inflammation, and ferroptosis pathways in rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 2025.
Related on Peak Human
Dosing Protocol
100 mg once dailymg
Standard starting dose based on research
Therapeutic Range
100
Minimum
300
Maximum
With a meal that contains some fat
Cycling Protocol
Not required; typically taken daily and ongoing.
Dosages are general guidelines. Individual requirements vary based on body weight, health status, and specific goals. Start with lower doses and adjust based on response.
Benefits
Primary Benefits
- Cell-membrane stability
- Mitochondrial support
- Metabolic and liver health markers
- Reduced inflammatory signalling (preclinical)
Secondary Benefits
Safety Information
Contraindications
Do not use if any of the following apply:
- •Known allergy to any product ingredient
Drug/Supplement Interactions
May interact with the following. Consult a healthcare provider before combining:
Potential Side Effects
Some users may experience:
This is not a complete list of interactions or side effects. Individual responses vary. Always start with the lowest effective dose and monitor your response. Report any adverse effects to your healthcare provider.
Quality Markers
Look for these specific quality indicators when sourcing this compound:
- Pure free-fatty-acid form of C15:0 (e.g., FA15)
- Third-party tested for purity
- Free of dairy and animal contaminants
Trusted Certifications
Note: Supplement quality varies dramatically between brands. Cheap supplements often contain fillers, incorrect doses, or contaminants. Investing in quality products from reputable manufacturers is essential for safety and efficacy.
Evidence Profile
Evidence Score
5/10
Moderate Evidence
Some clinical trials with positive results, emerging research
Evidence Scale
8-10
Strong
5-7
Moderate
1-4
Emerging
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation
